retatrutide fatty liver study Retatrutide—A Game Changer in Obesity Pharmacotherapy Efficacy and safety of anti-obesity

J Inflammation Res

In one clinical trial funded by Eli Lilly, participants who took Tirzepatide 5.0 mg lost 16.1 kg of body weight, participants who took Tirzepatide 10 mg lost 22.2 kg of body weight, and participants who took Tirzepatide 15 mg lost 23.6 kg of body weight, while only 2.4 kg weight loss was observed in participants taking placebo

Mistake 4: ignoring fiber Up to 30% of GLP-1 users experience constipation

Currently, there is only two classes of drugs approved for the treatment of AD: N-methyl D -aspartate (NMDA) antagonist (memantine), and cholinesterase inhibitors (tacrine, Donepezil, galantamine, rivastigmine)

Yes, many patients require a reduction in insulin doses to prevent low blood sugar levels

Although Part D beneficiaries are eligible, patients who receive GLP-1s through Bridge will not have those fills covered by Medicare Part D